Anbio Biotechnology is a Germany-based medical device company. The Company is engaged in the development of medical technology and the provision of in vitro diagnostics (IVD) products. Its products offer solutions for over the counter (OTC) use, point-of-care (POCT) settings, and laboratory applications, ensuring that both healthcare providers and patients have access to reliable and efficient diagnostic tools in any setting. Its IVD products detect a wide range of biomarkers across critical medical fields, including infectious diseases, cancer, cardiovascular diseases, inflammation, drug abuse, endocrine disorders, renal disease, pharmacogenomics, and diabetes. Some of its IVD platforms: Chemiluminescence Immunoassay (ChLIA), Lateral Flow Immunoassay (LFIA), Fluorescent Immunoassay (FIA), Polymerase Chain Reaction (PCR) and Loop-mediated Isothermal Amplification (LAMP).
企業コードNNNN
会社名Anbio Biotechnology
上場日Feb 19, 2025
最高経営責任者「CEO」Lau (Michael)
従業員数27
証券種類Ordinary Share
決算期末Feb 19
本社所在地Friedrich-Ebert-Anlage 49
都市FRANKFURT AM MAIN
証券取引所NASDAQ OMX - NASDAQ BASIC
国Germany
郵便番号60308
電話番号4916096247281
ウェブサイトhttps://anbiobiotechnology.com/
企業コードNNNN
上場日Feb 19, 2025
最高経営責任者「CEO」Lau (Michael)
過去5年間の配当金総支払額は
0.00
米ドルである。

データなし